Efforts to realize the implementation of professional, fair, transparent, and accountable public services continue to be carried out by the Directorate of Drug Production Supervision & NPP in order to implement Bureaucratic Reform to support the Development of the Integrity Zone. One of the efforts certainly requires the support of partners in overseeing the implementation of Bureaucratic Reform in order to continue to make improvements with the aim of providing excellent public services.
The support is implemented in accordance with the Regulation of the Minister of Administrative and Bureaucratic Reform Number 16 of 2017 concerning Guidelines for Organizing Public Consultation Forums in Public Service Provider Units. The Directorate of Drug Production Supervision & NPP has successfully held a Public Consultation Forum activity (20/06/2024) by inviting Business Actors, Ministries/Institutions, Associations, Organizations and the mass media, which are related to the use of services in the fields of drugs, drug raw materials, biological products. The activity aims to be one of Communication Channels for Regulators, Business Actors, and other stakeholders to capture "customer voice" from various service users, stakeholders and stakeholders related to gaining an understanding in recognizing the various challenges faced and practical solutions that can be implemented, in order to improve the quality of public service delivery at the Directorate of Drug Production Supervision and NPP.
The series of events for the Public Consultation Forum this time focuses on efforts to improve public services as follows:
1. Public Service Standards in the Directorate of Drug Production Supervision and NPP continue to strive to improve the quality of public services by carrying out various innovations and utilizing technology in services to facilitate and expand the reach of services and continue to coordinate and collaborate with other related and overlapping stakeholders so that the requirements can be harmonious and in line so as to facilitate their fulfillment. In addition, it was also explained regarding the review of GAP types of public services (CPOB Recertification and Application for Joint Use of Drug and Non-Drug Facilities) and Interventions to accelerate services. This was conveyed by the Director of Drug Production Supervision and NPP.
2. The Importance of Establishing Public Service Standards by involving the Community, is an important key in the provision of services, also as a reference for implementation guidelines that become a benchmark for certainty and clarity of the service process. The involvement of the Community and related parties is very necessary in the preparation of service standards so that the expected needs can be met. This was conveyed by the representative of the Assistant Deputy for Empowerment of Community Participation, Kemenpan RB.
3. Signing of the Minutes of the Public Consultation Forum and Commitment Building Activities as a manifestation of effective and efficient collaboration and commitment in the implementation of public services.
4. Readiness and Commitment of Business Actors in Compliance with Good Manufacturing Practices (CPOB), it is expected that the Pharmaceutical Industry must be ready and committed to fulfilling CPOB compliance in ensuring the quality, safety, and benefits of drugs as conveyed by the Secretary General of the Indonesian Pharmaceutical Companies Association (GPFI).
5. IAI's involvement in the competence of Responsible Pharmacists in the Pharmaceutical Industry plays a role in improving the competence of Responsible Pharmacists working in the Pharmaceutical Industry. Competence improvement is carried out through certification, annual scientific weeks and workshops and knowledge sharing. This was conveyed by the Chairperson of the Industrial Pharmacy Seminary Association/HISFARIN.
The Public Consultation Forum within the Directorate of Drug Production Supervision and NPP is expected to be a two-way medium to explore aspirations in order to improve the quality of public services so that it can provide added value and solutions in efforts to improve public services in accordance with the expectations and needs of stakeholders of the Directorate of Drug Production Supervision and NPP. In addition, it is expected to support the WHO Listed Authority (WLA) process and the re-assessment of PIC/S membership needed to maintain the recognition of the equality of the POM Agency's supervision system with international standards. This equality is expected to spur the Pharmaceutical Industry in increasing competitiveness in the international market.
Tel: (021) 4245459
English 
Indonesian